 | • レポートコード：20QY06-03007 • 出版社/出版日：QYResearch / 2020年6月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、ヒト組み換えインスリンのグローバル市場について種類別（速効型ヒトインスリン、レギュラー（短時間作用型）インスリン、NPH（中間作用型）インスリン、長時間作用型ヒトインスリン、プレミックスヒトインスリンインスリン）、用途別（病院、小売薬局、オンライン薬局、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・ヒト組み換えインスリン市場の概要 ・世界の主要地域別ヒト組み換えインスリン市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のヒト組み換えインスリン市場規模2015-2026：種類別（速効型ヒトインスリン、レギュラー（短時間作用型）インスリン、NPH（中間作用型）インスリン、長時間作用型ヒトインスリン、プレミックスヒトインスリンインスリン） ・世界のヒト組み換えインスリン市場規模2015-2026：用途別（病院、小売薬局、オンライン薬局、その他） ・ヒト組み換えインスリンの北米市場規模2015-2020 ・ヒト組み換えインスリンのヨーロッパ市場規模2015-2020 ・ヒト組み換えインスリンの中国市場規模2015-2020 ・ヒト組み換えインスリンの日本市場規模2015-2020 ・ヒト組み換えインスリンの東南アジア市場規模2015-2020 ・ヒト組み換えインスリンのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Novo Nordisk、Eli Lilly and Company、Sanofi、Julphar Gulf Pharmaceutical Industries、Bioton、Gan & Lee Pharmaceuticals、Zhuhai United Laboratories、Biocon、Wanbang Biopharmaceuticals、Dongbao Enterprise Group、PeproTech） ・ヒト組み換えインスリンの製造コスト分析 ・販売チャネル、流通業者、顧客 ・ヒト組み換えインスリンの市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Human Recombinant Insulin Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Human Recombinant Insulin market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Human Recombinant Insulin market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Human Recombinant Insulin industry.
Based on our recent survey, we have several different scenarios about the Human Recombinant Insulin YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Human Recombinant Insulin will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Human Recombinant Insulin market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Human Recombinant Insulin market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Human Recombinant Insulin market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Human Recombinant Insulin market. The report also includes nautical information, where it shows Human Recombinant Insulin market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Human Recombinant Insulin market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Human Recombinant Insulin market.
Geographical Analysis:
Based on region, the global Human Recombinant Insulin market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Human Recombinant Insulin market are
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech
Segment by Type
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Human Recombinant Insulin market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Human Recombinant Insulin market.
• The market share of the global Human Recombinant Insulin market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Human Recombinant Insulin market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Human Recombinant Insulin market.
1 Human Recombinant Insulin Market Overview
1.1 Human Recombinant Insulin Product Scope
1.2 Human Recombinant Insulin Segment by Type
1.2.1 Global Human Recombinant Insulin Sales by Type (2020-2026)
1.2.2 Rapid-Acting Human Insulin
1.2.3 Regular (Short Acting) Insulin
1.2.4 NPH (Intermediate Acting) Insulin
1.2.5 Long-Acting Human Insulin
1.2.6 Premixed Human Insulins Insulin
1.3 Human Recombinant Insulin Segment by Application
1.3.1 Global Human Recombinant Insulin Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Human Recombinant Insulin Market Estimates and Forecasts (2015-2026)
1.4.1 Global Human Recombinant Insulin Sales Growth Rate (2015-2026)
1.4.2 Global Human Recombinant Insulin Revenue and Growth Rate (2015-2026)
1.4.3 Global Human Recombinant Insulin Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Human Recombinant Insulin Industry Impact
1.5.1 How the Covid-19 is Affecting the Human Recombinant Insulin Industry
1.5.1.1 Human Recombinant Insulin Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Human Recombinant Insulin Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Human Recombinant Insulin Players to Combat Covid-19 Impact
2 Human Recombinant Insulin Estimate and Forecast by Region
2.1 Global Human Recombinant Insulin Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Human Recombinant Insulin Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Human Recombinant Insulin Sales Market Share by Region (2015-2020)
2.2.2 Global Human Recombinant Insulin Revenue Market Share by Region (2015-2020)
2.3 Global Human Recombinant Insulin Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Human Recombinant Insulin Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Human Recombinant Insulin Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Human Recombinant Insulin Estimates and Projections (2015-2026)
2.4.2 Europe Human Recombinant Insulin Estimates and Projections (2015-2026)
2.4.3 China Human Recombinant Insulin Estimates and Projections (2015-2026)
2.4.4 Japan Human Recombinant Insulin Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Human Recombinant Insulin Estimates and Projections (2015-2026)
2.4.6 India Human Recombinant Insulin Estimates and Projections (2015-2026)
3 Global Human Recombinant Insulin Competition Landscape by Players
3.1 Global Top Human Recombinant Insulin Players by Sales (2015-2020)
3.2 Global Top Human Recombinant Insulin Players by Revenue (2015-2020)
3.3 Global Human Recombinant Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Recombinant Insulin as of 2019)
3.4 Global Human Recombinant Insulin Average Price by Company (2015-2020)
3.5 Manufacturers Human Recombinant Insulin Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Human Recombinant Insulin Players (Opinion Leaders)
4 Global Human Recombinant Insulin Market Size by Type
4.1 Global Human Recombinant Insulin Historic Market Review by Type (2015-2020)
4.1.1 Global Human Recombinant Insulin Sales Market Share by Type (2015-2020)
4.1.2 Global Human Recombinant Insulin Revenue Market Share by Type (2015-2020)
4.1.3 Global Human Recombinant Insulin Price by Type (2014-2020)
4.2 Global Human Recombinant Insulin Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Human Recombinant Insulin Sales Forecast by Type (2021-2026)
4.2.2 Global Human Recombinant Insulin Revenue Forecast by Type (2021-2026)
4.2.3 Global Human Recombinant Insulin Price Forecast by Type (2021-2026)
5 Global Human Recombinant Insulin Market Size by Application
5.1 Global Human Recombinant Insulin Historic Market Review by Application (2015-2020)
5.1.1 Global Human Recombinant Insulin Sales Market Share by Application (2015-2020)
5.1.2 Global Human Recombinant Insulin Revenue Market Share by Application (2015-2020)
5.1.3 Global Human Recombinant Insulin Price by Application (2015-2020)
5.2 Global Human Recombinant Insulin Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Human Recombinant Insulin Sales Forecast by Application (2021-2026)
5.2.2 Global Human Recombinant Insulin Revenue Forecast by Application (2021-2026)
5.2.3 Global Human Recombinant Insulin Price Forecast by Application (2021-2026)
3 North America Human Recombinant Insulin Market Facts & Figures
3.2 North America Human Recombinant Insulin Sales Market Share by Company (2015-2020)
3.3 North America Human Recombinant Insulin Sales Market Share by Type (2015-2020)
3.4 North America Human Recombinant Insulin Sales Market Share by Application (2015-2020)
4 Europe Human Recombinant Insulin Market Facts & Figures
4.2 Europe Human Recombinant Insulin Sales Market Share by Company (2015-2020)
4.3 Europe Human Recombinant Insulin Sales Market Share by Type (2015-2020)
4.4 Europe Human Recombinant Insulin Sales Market Share by Application (2015-2020)
5 China Human Recombinant Insulin Market Facts & Figures
5.2 China Human Recombinant Insulin Sales Market Share by Company (2015-2020)
5.3 China Human Recombinant Insulin Sales Market Share by Type (2015-2020)
5.4 China Human Recombinant Insulin Sales Market Share by Application (2015-2020)
6 Japan Human Recombinant Insulin Market Facts & Figures
6.2 Japan Human Recombinant Insulin Sales Market Share by Company (2015-2020)
6.3 Japan Human Recombinant Insulin Sales Market Share by Type (2015-2020)
6.4 Japan Human Recombinant Insulin Sales Market Share by Application (2015-2020)
7 Southeast Asia Human Recombinant Insulin Market Facts & Figures
7.2 Southeast Asia Human Recombinant Insulin Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Human Recombinant Insulin Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Human Recombinant Insulin Sales Market Share by Application (2015-2020)
8 India Human Recombinant Insulin Market Facts & Figures
8.2 India Human Recombinant Insulin Sales Market Share by Company (2015-2020)
8.3 India Human Recombinant Insulin Sales Market Share by Type (2015-2020)
8.4 India Human Recombinant Insulin Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Human Recombinant Insulin Business
12.1 Novo Nordisk
12.1.1 Novo Nordisk Human Recombinant Insulin Corporation Information
12.1.2 Novo Nordisk Human Recombinant Insulin Business Overview and Total Revenue
12.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novo Nordisk Human Recombinant Insulin Products Offered
12.1.5 Novo Nordisk Recent Development
12.2 Eli Lilly and Company
12.2.1 Eli Lilly and Company Human Recombinant Insulin Corporation Information
12.2.2 Eli Lilly and Company Human Recombinant Insulin Business Overview and Total Revenue
12.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Eli Lilly and Company Human Recombinant Insulin Products Offered
12.2.5 Eli Lilly and Company Recent Development
12.3 Sanofi
12.3.1 Sanofi Human Recombinant Insulin Corporation Information
12.3.2 Sanofi Human Recombinant Insulin Business Overview and Total Revenue
12.3.3 Sanofi Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Sanofi Human Recombinant Insulin Products Offered
12.3.5 Sanofi Recent Development
12.4 Julphar Gulf Pharmaceutical Industries
12.4.1 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Corporation Information
12.4.2 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Business Overview and Total Revenue
12.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Products Offered
12.4.5 Julphar Gulf Pharmaceutical Industries Recent Development
12.5 Bioton
12.5.1 Bioton Human Recombinant Insulin Corporation Information
12.5.2 Bioton Human Recombinant Insulin Business Overview and Total Revenue
12.5.3 Bioton Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Bioton Human Recombinant Insulin Products Offered
12.5.5 Bioton Recent Development
12.6 Gan & Lee Pharmaceuticals
12.6.1 Gan & Lee Pharmaceuticals Human Recombinant Insulin Corporation Information
12.6.2 Gan & Lee Pharmaceuticals Human Recombinant Insulin Business Overview and Total Revenue
12.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Gan & Lee Pharmaceuticals Human Recombinant Insulin Products Offered
12.6.5 Gan & Lee Pharmaceuticals Recent Development
12.7 Zhuhai United Laboratories
12.7.1 Zhuhai United Laboratories Human Recombinant Insulin Corporation Information
12.7.2 Zhuhai United Laboratories Human Recombinant Insulin Business Overview and Total Revenue
12.7.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Zhuhai United Laboratories Human Recombinant Insulin Products Offered
12.7.5 Zhuhai United Laboratories Recent Development
12.8 Biocon
12.8.1 Biocon Human Recombinant Insulin Corporation Information
12.8.2 Biocon Human Recombinant Insulin Business Overview and Total Revenue
12.8.3 Biocon Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Biocon Human Recombinant Insulin Products Offered
12.8.5 Biocon Recent Development
12.9 Wanbang Biopharmaceuticals
12.9.1 Wanbang Biopharmaceuticals Human Recombinant Insulin Corporation Information
12.9.2 Wanbang Biopharmaceuticals Human Recombinant Insulin Business Overview and Total Revenue
12.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Wanbang Biopharmaceuticals Human Recombinant Insulin Products Offered
12.9.5 Wanbang Biopharmaceuticals Recent Development
12.10 Dongbao Enterprise Group
12.10.1 Dongbao Enterprise Group Human Recombinant Insulin Corporation Information
12.10.2 Dongbao Enterprise Group Human Recombinant Insulin Business Overview and Total Revenue
12.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Dongbao Enterprise Group Human Recombinant Insulin Products Offered
12.10.5 Dongbao Enterprise Group Recent Development
12.11 PeproTech
12.11.1 PeproTech Human Recombinant Insulin Corporation Information
12.11.2 PeproTech Human Recombinant Insulin Business Overview and Total Revenue
12.11.3 PeproTech Human Recombinant Insulin Sales, Revenue and Gross Margin (2015-2020)
12.11.4 PeproTech Human Recombinant Insulin Products Offered
12.11.5 PeproTech Recent Development
13 Human Recombinant Insulin Manufacturing Cost Analysis
13.1 Human Recombinant Insulin Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Human Recombinant Insulin
13.4 Human Recombinant Insulin Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Human Recombinant Insulin Distributors List
14.3 Human Recombinant Insulin Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Human Recombinant Insulin Sales (K Litre) Growth Rate by Type (2020-2026)
Table 2. Global Human Recombinant Insulin Sales (K Litre) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Human Recombinant Insulin Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Human Recombinant Insulin Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Human Recombinant Insulin Players to Combat Covid-19 Impact
Table 8. Global Market Human Recombinant Insulin Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Human Recombinant Insulin Sales (K Litre) by Region (2015-2020)
Table 10. Global Human Recombinant Insulin Sales Market Share by Region (2015-2020)
Table 11. Global Human Recombinant Insulin Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Human Recombinant Insulin Revenue Share by Region (2015-2020)
Table 13. Global Human Recombinant Insulin Sales (K Litre) Forecast by Region (2021-2026)
Table 14. Global Human Recombinant Insulin Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Human Recombinant Insulin Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Human Recombinant Insulin Revenue Share Forecast by Region (2021-2026)
Table 17. Global Human Recombinant Insulin (K Litre) of Key Companies (2015-2020)
Table 18. Global Human Recombinant Insulin Sales Share by Company (2015-2020)
Table 19. Global Human Recombinant Insulin Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Human Recombinant Insulin Revenue Share by Company (2015-2020)
Table 21. Global Human Recombinant Insulin by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Recombinant Insulin as of 2019)
Table 22. Global Human Recombinant Insulin Average Price (USD/Litre) of Key Company (2015-2020)
Table 23. Manufacturers Human Recombinant Insulin Manufacturing Sites and Area Served
Table 24. Manufacturers Human Recombinant Insulin Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Human Recombinant Insulin Players
Table 27. Global Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 28. Global Human Recombinant Insulin Sales Share by Type (2015-2020)
Table 29. Global Human Recombinant Insulin Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Human Recombinant Insulin Price (K Litre) by Type (2015-2020)
Table 31. Global Human Recombinant Insulin Sales Share by Type (2021-2026)
Table 32. Global Human Recombinant Insulin Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Human Recombinant Insulin Revenue Share by Type (2021-2026)
Table 34. Global Human Recombinant Insulin Price (K Litre) by Type (2021-2026)
Table 35. Global Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 36. Global Human Recombinant Insulin Sales Share by Application (2015-2020)
Table 37. Global Human Recombinant Insulin Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Human Recombinant Insulin Price (K Litre) by Application (2015-2020)
Table 39. Global Human Recombinant Insulin Sales (K Litre) by Application (2021-2026)
Table 40. Global Human Recombinant Insulin Sales Share by Application (2021-2026)
Table 41. Global Human Recombinant Insulin Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Human Recombinant Insulin Revenue Share by Application (2021-2026)
Table 43. Global Human Recombinant Insulin Price (K Litre) by Application (2021-2026)
Table 44. United States Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 45. United States Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 46. United States Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 47. United States Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 48. United States Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 49. United States Human Recombinant Insulin Sales Market Share by Application (2015-2020)
Table 50. Europe Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 51. Europe Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 52. Europe Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 53. Europe Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 54. Europe Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 55. Europe Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 56. China Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 57. China Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 58. China Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 59. China Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 60. China Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 61. China Human Recombinant Insulin Sales Market Share by Application (2015-2020)
Table 62. Japan Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 63. Japan Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 64. Japan Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 65. Japan Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 66. Japan Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 67. Japan Human Recombinant Insulin Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 69. Southeast Asia Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 71. Southeast Asia Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 73. Southeast Asia Human Recombinant Insulin Sales Market Share by Application (2015-2020)
Table 74. India Human Recombinant Insulin Sales (K Litre) by Company (2015-2020)
Table 75. India Human Recombinant Insulin Sales Market Share by Company (2015-2020)
Table 76. India Human Recombinant Insulin Sales (K Litre) by Type (2015-2020)
Table 77. India Human Recombinant Insulin Sales Market Share by Type (2015-2020)
Table 78. India Human Recombinant Insulin Sales (K Litre) by Application (2015-2020)
Table 79. India Human Recombinant Insulin Sales Market Share by Application (2015-2020)
Table 80. Novo Nordisk Corporation Information
Table 81. Novo Nordisk Description and Business Overview
Table 82. Novo Nordisk Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 83. Novo Nordisk Human Recombinant Insulin Product
Table 84. Novo Nordisk Recent Development
Table 85. Eli Lilly and Company Corporation Information
Table 86. Eli Lilly and Company Description and Business Overview
Table 87. Eli Lilly and Company Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 88. Eli Lilly and Company Human Recombinant Insulin Product
Table 89. Eli Lilly and Company Recent Development
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 93. Sanofi Human Recombinant Insulin Product
Table 94. Sanofi Recent Development
Table 95. Julphar Gulf Pharmaceutical Industries Corporation Information
Table 96. Julphar Gulf Pharmaceutical Industries Description and Business Overview
Table 97. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 98. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product
Table 99. Julphar Gulf Pharmaceutical Industries Recent Development
Table 100. Bioton Corporation Information
Table 101. Bioton Description and Business Overview
Table 102. Bioton Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 103. Bioton Human Recombinant Insulin Product
Table 104. Bioton Recent Development
Table 105. Gan & Lee Pharmaceuticals Corporation Information
Table 106. Gan & Lee Pharmaceuticals Description and Business Overview
Table 107. Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 108. Gan & Lee Pharmaceuticals Human Recombinant Insulin Product
Table 109. Gan & Lee Pharmaceuticals Recent Development
Table 110. Zhuhai United Laboratories Corporation Information
Table 111. Zhuhai United Laboratories Description and Business Overview
Table 112. Zhuhai United Laboratories Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 113. Zhuhai United Laboratories Human Recombinant Insulin Product
Table 114. Zhuhai United Laboratories Recent Development
Table 115. Biocon Corporation Information
Table 116. Biocon Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 117. Biocon Description and Business Overview
Table 118. Biocon Human Recombinant Insulin Product
Table 119. Biocon Recent Development
Table 120. Wanbang Biopharmaceuticals Corporation Information
Table 121. Wanbang Biopharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 122. Wanbang Biopharmaceuticals Description and Business Overview
Table 123. Wanbang Biopharmaceuticals Human Recombinant Insulin Product
Table 124. Wanbang Biopharmaceuticals Recent Development
Table 125. Dongbao Enterprise Group Corporation Information
Table 126. Dongbao Enterprise Group Description and Business Overview
Table 127. Dongbao Enterprise Group Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table 128. Dongbao Enterprise Group Human Recombinant Insulin Product
Table 129. Dongbao Enterprise Group Recent Development
Table . PeproTech Corporation Information
Table . PeproTech Description and Business Overview
Table . PeproTech Human Recombinant Insulin Sales (K Litre), Revenue (Million USD), Price (USD/Litre) and Gross Margin (2015-2020)
Table . PeproTech Human Recombinant Insulin Product
Table . PeproTech Recent Development
Table 135. Production Base and Market Concentration Rate of Raw Material
Table 136. Key Suppliers of Raw Materials
Table 137. Human Recombinant Insulin Distributors List
Table 138. Human Recombinant Insulin Customers List
Table 139. Market Key Trends
Table 140. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 141. Key Challenges
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Recombinant Insulin Product Picture
Figure 2. Global Human Recombinant Insulin Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Human Recombinant Insulin Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Retail Pharmacy Examples
Figure 8. Online Pharmacies Examples
Figure 9. Other Examples
Figure 10. Global Human Recombinant Insulin Sales (K Litre) Growth Rate (2015-2026)
Figure 11. Global Human Recombinant Insulin Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Human Recombinant Insulin Price Trends Growth Rate (2015-2026) (USD/Litre)
Figure 13. Global Human Recombinant Insulin Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Human Recombinant Insulin Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Human Recombinant Insulin Sales (K Litre) Growth Rate (2015-2026)
Figure 17. Europe Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Human Recombinant Insulin Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Human Recombinant Insulin Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Human Recombinant Insulin Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Human Recombinant Insulin Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Human Recombinant Insulin Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Human Recombinant Insulin Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Human Recombinant Insulin Players Market Share by Revenue in Human Recombinant Insulin 2015 & 2019
Figure 28. Human Recombinant Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Human Recombinant Insulin Revenue Share by Type (2015-2020)
Figure 30. Global Human Recombinant Insulin Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Human Recombinant Insulin Revenue Share by Application (2015-2020)
Figure 32. Global Human Recombinant Insulin Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 34. United States Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 35. Europe Human Recombinant Insulin Sales Market Share by Company in 2019
Figure 36. Europe Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 37. Europe Human Recombinant Insulin Sales Market Share by Application in 2019
Figure 38. China Human Recombinant Insulin Sales Market Share by Company in 2019
Figure 39. China Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 40. China Human Recombinant Insulin Sales Market Share by Application in 2019
Figure 41. Japan Human Recombinant Insulin Sales Market Share by Company in 2019
Figure 42. Japan Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 43. Japan Human Recombinant Insulin Sales Market Share by Application in 2019
Figure 44. Southeast Asia Human Recombinant Insulin Sales Market Share by Company in 2019
Figure 45. Southeast Asia Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 46. Southeast Asia Human Recombinant Insulin Sales Market Share by Application in 2019
Figure 47. India Human Recombinant Insulin Sales Market Share by Company in 2019
Figure 48. India Human Recombinant Insulin Sales Market Share by Type in 2019
Figure 49. India Human Recombinant Insulin Sales Market Share by Application in 2019
Figure 50. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Julphar Gulf Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Bioton Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Gan & Lee Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Zhuhai United Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Wanbang Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Dongbao Enterprise Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. PeproTech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Key Raw Materials Price Trend
Figure 62. Manufacturing Cost Structure of Human Recombinant Insulin
Figure 63. Manufacturing Process Analysis of Human Recombinant Insulin
Figure 64. Human Recombinant Insulin Industrial Chain Analysis
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
Figure 67. Porter's Five Forces Analysis
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
組換えヒトエンドスタチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Recombinant Human Endostatin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Recombinant Huma…- インスリンの世界市場レポート2020 A recently published report by QY Research titled Global Insulin Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a …
- インスリンリスプロの世界市場レポート2020 Insulin lispro is synthetic insulin with a very rapid onset and short duration of action. Diabetic patients typically use it immediately before meals to prevent postprandial hyperglycemia. Its absorption is more rapid than regular insulin. It is made by reversing the amino acids lysine and proline i…
- 組換えヒトアルブミンの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Recombinant Human Albumin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Recombinant Human A…
- インスリンAPIの世界市場レポート2020 A recently published report by QY Research titled Global Insulin API Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data i…